Published in J Neurochem on February 01, 2002
Amyotrophic lateral sclerosis. Orphanet J Rare Dis (2009) 2.76
Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.73
Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A (2004) 2.26
Neuronal degeneration and mitochondrial dysfunction. J Clin Invest (2003) 2.00
Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron (2010) 1.65
Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry (2005) 1.55
DNA repair deficiency in neurodegeneration. Prog Neurobiol (2011) 1.55
A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci (2006) 1.52
ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci (2003) 1.46
Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron (2013) 1.45
A role for mitochondrial dysfunction in perpetuating radiation-induced genomic instability. Cancer Res (2006) 1.34
Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst) (2008) 1.31
Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol (2009) 1.31
Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci (2009) 1.26
Mutant SOD1G93A triggers mitochondrial fragmentation in spinal cord motor neurons: neuroprotection by SIRT3 and PGC-1α. Neurobiol Dis (2012) 1.26
Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem (2011) 1.24
The neurodegenerative mitochondriopathies. J Alzheimers Dis (2009) 1.14
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics (2015) 1.05
Mitochondrial degeneration in amyotrophic lateral sclerosis. J Bioenerg Biomembr (2004) 1.02
The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front Cell Neurosci (2014) 1.02
Alterations in mitochondrial DNA copy number and the activities of electron transport chain complexes and pyruvate dehydrogenase in the frontal cortex from subjects with autism. Transl Psychiatry (2013) 0.99
Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice. J Biol Chem (2011) 0.97
Mitochondria in neurodegeneration. Adv Exp Med Biol (2012) 0.97
Isolated cytochrome c oxidase deficiency in G93A SOD1 mice overexpressing CCS protein. J Biol Chem (2008) 0.94
Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones from mouse. J Physiol (2003) 0.93
SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. Oxid Med Cell Longev (2013) 0.93
Mitochondrial medicine for neurodegenerative diseases. Int J Biochem Cell Biol (2010) 0.93
The wobbler mouse, an ALS animal model. Mol Genet Genomics (2013) 0.92
A fruitful endeavor: modeling ALS in the fruit fly. Brain Res (2014) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Measures of bulbar and spinal motor function, muscle innervation, and mitochondrial function in ALS rats. Behav Brain Res (2010) 0.90
Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev (2013) 0.86
Human stanniocalcin-1 suppresses angiotensin II-induced superoxide generation in cardiomyocytes through UCP3-mediated anti-oxidant pathway. PLoS One (2012) 0.86
Metabolic Dysfunctions in Amyotrophic Lateral Sclerosis Pathogenesis and Potential Metabolic Treatments. Front Neurosci (2017) 0.86
Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. Am J Physiol Cell Physiol (2010) 0.85
ALS spinal neurons show varied and reduced mtDNA gene copy numbers and increased mtDNA gene deletions. Mol Neurodegener (2010) 0.84
Differentiation of Human Neural Stem Cells into Motor Neurons Stimulates Mitochondrial Biogenesis and Decreases Glycolytic Flux. Stem Cells Dev (2015) 0.83
VDAC3 has differing mitochondrial functions in two types of striated muscles. Biochim Biophys Acta (2010) 0.82
Mitochondria-targeted catalase reverts the neurotoxicity of hSOD1G⁹³A astrocytes without extending the survival of ALS-linked mutant hSOD1 mice. PLoS One (2014) 0.82
PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro (2013) 0.82
Expression of zinc-deficient human superoxide dismutase in Drosophila neurons produces a locomotor defect linked to mitochondrial dysfunction. Neurobiol Aging (2013) 0.81
The interplay between metabolic homeostasis and neurodegeneration: insights into the neurometabolic nature of amyotrophic lateral sclerosis. Cell Regen (Lond) (2015) 0.80
Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation. Mol Cell Ther (2014) 0.80
The effect of SOD1 mutation on cellular bioenergetic profile and viability in response to oxidative stress and influence of mutation-type. PLoS One (2013) 0.79
Respiratory chain deficiency in aged spinal motor neurons. Neurobiol Aging (2014) 0.79
Differences in F-Wave Characteristics between Spinobulbar Muscular Atrophy and Amyotrophic Lateral Sclerosis. Front Aging Neurosci (2016) 0.79
Mitochondrial CHCHD-Containing Proteins: Physiologic Functions and Link with Neurodegenerative Diseases. Mol Neurobiol (2016) 0.77
Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener (2015) 0.77
Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach. J Biomark (2013) 0.76
Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients. J Neurol (2015) 0.76
Impaired Autophagy and Defective Mitochondrial Function: Converging Paths on the Road to Motor Neuron Degeneration. Front Cell Neurosci (2016) 0.76
Cysteine Modifications in the Pathogenesis of ALS. Front Mol Neurosci (2017) 0.75
Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun (2014) 0.75
Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinson's Disease? Curr Genomics (2009) 0.75
Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. Eur J Nucl Med Mol Imaging (2016) 0.75
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration. Front Immunol (2017) 0.75
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Mitochondrial respiratory-chain diseases. N Engl J Med (2003) 8.68
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet (2002) 6.02
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A (2008) 4.97
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Parkinson's disease. Hum Mol Genet (2007) 3.84
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol (2008) 3.35
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Mitochondrial disorders in the nervous system. Annu Rev Neurosci (2008) 2.93
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A (2004) 2.77
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem (2002) 2.68
Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2005) 2.58
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab (2009) 2.45
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
A Variegated Squirrel Bornavirus Associated with Fatal Human Encephalitis. N Engl J Med (2015) 2.34
In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab (2011) 2.33
Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet (2002) 2.20
Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol (2002) 2.13
Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res (2006) 2.11
Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A (2010) 2.10
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest (2005) 2.08
Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med (2002) 2.08
Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. PLoS Biol (2004) 2.02
Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci (2002) 2.01
Neuronal degeneration and mitochondrial dysfunction. J Clin Invest (2003) 2.00
Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med (2010) 1.91
Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol (2010) 1.91
Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res (2005) 1.90
Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci (2012) 1.80
The energetics of Huntington's disease. Neurochem Res (2004) 1.79
Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci (2005) 1.79
Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal (2006) 1.79
Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int (2008) 1.76
Assay of mitochondrial ATP synthesis in animal cells and tissues. Methods Cell Biol (2007) 1.76
High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet (2002) 1.75
The clinical maze of mitochondrial neurology. Nat Rev Neurol (2013) 1.72
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem (2006) 1.64
Mitochondrial nucleoids maintain genetic autonomy but allow for functional complementation. J Cell Biol (2008) 1.63
Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet (2009) 1.63
Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord (2005) 1.62
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells. J Biol Chem (2008) 1.61
Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc Natl Acad Sci U S A (2007) 1.60
Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A (2007) 1.58
Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med (2010) 1.57
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation (2011) 1.56
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci (2004) 1.54
The role of mitochondria in inherited neurodegenerative diseases. J Neurochem (2006) 1.53
Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J (2012) 1.53
Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology (2003) 1.50
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol (2013) 1.49
Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci (2008) 1.48
Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J (2009) 1.47
Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol (2005) 1.46
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2005) 1.46
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve (2007) 1.45
Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J (2010) 1.44
Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci (2005) 1.44
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet (2011) 1.44
Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J Neurochem (2005) 1.44
Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev (2005) 1.43
Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol (2013) 1.43
PGC-1alpha, a new therapeutic target in Huntington's disease? Cell (2006) 1.42
The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum Mol Genet (2004) 1.40
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci (2007) 1.40
Two direct repeats cause most human mtDNA deletions. Trends Genet (2004) 1.39
Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol Aging (2004) 1.37
Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci (2009) 1.36
Biochemical analysis of respiratory function in cybrid cell lines harbouring mitochondrial DNA mutations. Biochem J (2004) 1.36
Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol Aging (2004) 1.36
Alzheimer's APP mangles mitochondria. Nat Med (2006) 1.36
Different regulation of wild-type and mutant Cu,Zn superoxide dismutase localization in mammalian mitochondria. Hum Mol Genet (2008) 1.35
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta (2008) 1.35
Risk of developing a mitochondrial DNA deletion disorder. Lancet (2004) 1.34